Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 72

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 72
---
     |            62,278 |
| Investor relations                                        |     |   210,954 |     |                  - |     |   440,484 |     |                 - |
|                                                           |     | 2,201,911 |     |            186,418 |     | 6,008,493 |     |           725,957 |

Professional fees increased by $1,012,272 or 810% and $2,327,679 or 481% for the three and nine months ended September 30, 2024, respectively, compared to the equivalent periods in the prior year. The increase was primarily due to increases in legal and accounting fees related to the Company's registration statement filing with the U.S. Securities and Exchange Commission.

Consulting fees increased by $357,405 or 596% and $1,176,599 or 654% for the three and nine months ended September 30, 2024, respectively, compared to the equivalent periods in the prior year. Consulting fees include fees paid to individuals and professional firms who provide advisory services to the Company and fluctuate from period to period based on the nature of the transactions the Company undertakes.

Salaries, wages and benefits increased by $279,358 or 100% and $819,717 or 100% for the three and nine months ended September 30, 2024, respectively, compared to the equivalent periods in the prior year. The Company did not have employees in the equivalent periods of the prior year.

General office, insurance and administration expenditures increased by $155,054 or 10271% and $518,057 832% for the three and nine months ended September 30, 2024, respectively, compared to the equivalent periods in the prior year. The increase was primarily due to the Company now incurring more significant insurance related expenses and general office related expenditures in support of expanded operations.

Investor relations costs increased by $210,954 or 100% and $440,484 or 100% for the three and nine months ended September 30, 2024, respectively, compared to the equivalent periods in the prior year. Investor relations expenses for the three and nine months ended September 30, 2024, were incurred as a result of the Company becoming a listed public entity after the RTO transaction.

There is an expected increase in general and administrative expenses associated with being a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services